

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Current Insight into Specific Cellular Immunity of Women Presenting with HPV16-Related Vulvar Intra-Epithelial Neoplasia and Their Partners

Isabelle Bourgault-Villada

*AP-HP, Hôpital Ambroise Paré, Boulogne Billancourt,
UVSQ, Versailles,
France*

1. Introduction

The premalignant lesions of vulvar intraepithelial neoplasia (VIN) involve the mucosal and/or cutaneous epithelium of the vulva. VIN may be HPV-related VIN (usual VIN) or – unrelated and represents the most frequent vulvar cancer precursors. Usual VIN occurs in adult women and commonly resembles persistent anogenital warts which are often multifocal pigmented papular lesions. It is caused by high-risk HPV (HR-HPV) types, essentially 16 in up to 91% of the cases (Srodon et al, 2006), and histologically, it is made of poorly to undifferentiated basal cells and/or highly atypical squamous epithelial cells (McClugagge et al, 2009). The involvement of the entire thickness of the epithelium defines the grade 3 of the disease (VIN3). The disease progresses towards invasion in about 3% of treated patients and 9% of the untreated ones according to a review of over 3,000 cases (van Seters et al, 2005) whereas evolution towards invasive carcinoma is observed in about 30% of untreated grade 3 cervical intraepithelial neoplasia (CIN3) patients (Ostor et al, 1993).

2. Virology

HPVs are DNA viruses with a circular double strain genome including 8 000 base pairs. The genome is divided into three regions: a Long Control Region which controls viral replication, a region coding for Early proteins (E1 to E7, including the E6 and E7 proteins that share oncogenic and transforming properties), and a region coding for Late proteins such as L1 and L2 proteins that constitute 80% and 20% of the viral capsid, respectively. More than 150 HPV have been sequenced, one HPV being considered different from another when there is a difference in 10% of nucleotides coding for L1 genes.

Following a breach in the malpighian pluristratified epithelium, HPVs infect basal stem cells of keratinocytes. The virus initially remains in episomal form with synthesis of E2 protein. This protein is a major regulator of viral vegetative cycle and is required for transcriptional

regulation as well as viral DNA replication together with the E1 helicase (Desaintes et al, 1996). In contrast, E2 is generally undetectable in cancers due to a preferential integration of the viral genome in the cell genome and disruption of the E2 open reading frame (Berumen et al, 1994; Collins et al, 2009). Therefore E2 is a marker of viral infection and is specific for the early stages of the viral gene expression in infected cells. This was formally demonstrated in a recent work that showed a strong staining of the E2 protein in the intermediate differentiated layers of HPV16-infected tissues and low grade CIN (Xue et al, 2010). The high expression of HPV16 E2 in low grade lesions therefore represents a marker for HPV infection even before any clinical manifestation.

After integration of the genome of oncogenic HPVs such as HPV16 into the host genome, viral oncogenic E6 and E7 proteins are synthesized in large quantities in the inner third of the epithelium. E6 links to p53 and induces its degradation by the ubiquitin pathway and E7 links to pRB and allows the release of growth factors such as E2F.

During maturation of keratinocytes from the basal layer to the epithelial surface, viral capsid proteins L1 and L2 are synthesized and expressed at the surface of mature keratinocytes in order to form a new viral particle which is able to infect adjacent healthy epithelium and to contaminate sexual partners.

3. Epidemiology of HPV16 related VIN

HPV infections occur preferentially in young women under 25 years of age (Boulanger et al, 2004). Several stages of lesions can be observed following oncogenic HPV infection. The first stage is a simple infection of keratinocytes that become koilocytes. The following stages are related to the transformation of infected keratinocytes into malignant cells. The depth at which malignant cells are found defines the disease stage. High grade squamous intraepithelial lesions as VIN3 are diagnosed on the basis of biopsy, with malignant cells in entire thickness of the epithelium

The premalignant lesions of HPV-related grade 3 intraepithelial neoplasia involve the mucosal and/or cutaneous epithelium of the vulva (usual VIN or VIN3), perineal and perianal region. Usual VIN occurs in adult women and commonly resembles persistent anogenital warts that are more often multifocal pigmented papular lesions disseminated on the vulva and/or the perianal skin than monofocal unique lesion (Figure 1).





Fig. 1. Clinical presentations of usual multifocal or monofocal vulvar and preineal intraepithelial neoplasia

4. Why does usual VIN can spontaneously regress?

Although usual VIN lesions are often chronic and recurrent, they can regress spontaneously in up to 35% of young (less than 30 years) women presenting with multiple pigmented lesions within a median duration of 9.5 months (Jones et al, 2005} (Bourgault Villada, 2010). We previously studied a patient who presented with multifocal usual VIN and showed a complete clearance of viral lesions eight months after disease onset and two months after electrocoagulation of less than 50% of the usual VIN lesions (Bourgault Villada et al, 2004). Immunohistochemical study of her initial vulvar biopsy revealed a marked dermal infiltrate containing a majority of CD4⁺ T lymphocytes and an epidermal infiltrate made up of both CD4⁺ and CD8⁺ T cells (Figure 2). She showed also a proliferating response against one peptide from E6 protein and a high frequency anti-E6 and anti-E7 effector blood T cells by *ex vivo* IFN γ - ELISpot assay just before clinical regression (Figure 3). Such a study of blood cellular immune responses together with the analysis of vulvar biopsies obtained simultaneously and correlated to clinical outcome was not previously reported. In an anti-HPV vaccine trial conducted by Davidson and al (Davidson et al, 2003), usual VIN lesions completely regressed in a patient following vaccination. Interestingly, immunostaining of

vulvar biopsy prior to the vaccine showed a marked CD4+ and CD8+ T lymphocyte infiltrate of both epithelial and sub-epithelial sheets. One may wonder whether the regression of these patient lesions could be related to a spontaneous regression. Therefore, the observation of a CD4+ and CD8+ infiltrate within sub-epithelial and epithelial sheets in the biopsy and the visualization of very strong blood anti-HPV T cell responses in patient with usual VIN could be predictive of spontaneous clinical outcome. It may also be thought that high numbers of blood CD4+ and CD8+ lymphocytes after therapeutic vaccination could allow clearance of HPV-16 lesions in usual VIN, assuming that anti-HPV vaccine-induced T effector cells could home in the HPV cutaneous and mucosal lesions.




Fig. 2. Immunohistochemical study of the vulvar biopsy just before spontaneous regression




Fig. 3. IFN γ -ELISpot assay performed just before clinical regression

5. What is the exact role of cellular HPV16-specific T-cell responses?

Cellular immunity (CD4+ and CD8+ T-cells) plays a key role in the defense against all HPV-induced infections or lesions by destroying HPV-infected or -transformed keratinocytes. Indeed, the incidence of HPV infections and diseases significantly increases with CD4+ T cell impairment in immunosuppressed such as transplanted (Arends et al, 1997) or HIV-infected

patients (Sun et al, 1997). In asymptomatic HPV16 infections, most women resolve spontaneously their infection without clinical disease concomitantly with blood anti-HPV16 Th1 CD4+ T cell responses (Welters et al, 2003). Similarly, regression of condyloma is associated with a dense epithelial cellular infiltrate made up of both CD4+ and CD8+ T lymphocytes with a Th1 cytokine profile as measured by cytokine mRNAs in interferon (IFN)-treated condylomas (Coleman et al, 1994). Proliferative CD4+ T cell responses are also associated with spontaneously regressive CIN3 (Kadish et al, 1997). The evolution of CIN3 towards invasive cancers is featured by a decrease of CD4+ cellular infiltrate, an increase of CD8+ T lymphocytes (Ghosh et al, 1992) with impairment of HPV16-specific CTL responses which could be related to a down-regulation of MHC class I molecules on HPV-16-infected cells and to the appearance of suppressive T lymphocytes (Treg) and a loss of blood anti-HPV-16 CD4+ activity. In high grade cervical intraepithelial neoplasia (CIN), positive intra-dermal reaction after intra-dermal injection of 5 HPV-16 E7 large peptides correlated with the spontaneous clearance of the lesions, which further indicates the presence and the very important role of HPV specific CD4+ T lymphocytes (Hopfl et al, 2000).

6. Anti-E2 T-cell responses are a marker of clinical viral control

We recently tested in a longitudinal study of 18 months, by proliferative assays, intracellular cytokines synthesis and IFN γ -ELISpot, the cellular immune responses against the HPV16 E2 protein that is early synthesized after HPV infection when the virus is episomal in eight women presenting with HPV16-related usual VIN and their healthy male partners (Jacobelli et al, 2011, unpublished data). In six women, we showed that anti-E2 polyfunctional CD4 T-cell responses (proliferative responses and synthesis of IFN γ and/or IL2) appear when the clinical lesions heal after treatment or when the HPV infection remains silent. In the women presenting with persistent lesions, no proliferation was observed.

Blood proliferative T-cell responses against HPV16 E2 peptides have been also observed in 50% of healthy women, who presumably previously cleared HPV16 infection (de Jong et al, 2004) and in 9 out of 22 regressive CIN3 cases (Dillon et al, 2007). In another studies, the lack of anti-E2 proliferative responses was reported in 16 of 18 patients (89%) affected with usual VIN lesions (Davidson et al, 2003) and in 7 of 8 and 9 of 12 women affected with CIN3 (Dillon et al, 2007; de Jong et al, 2004). These observations reinforce the strong role of T-cells in the control of HPV replication.

7. Why the male partners do not have any HPV16-related lesions?

Men are vectors of oncogenic HPV infection (Buckley et al, 1981; Giuliano et al, 2011). However, while HPV infection was found in 71 to 90% of the partners of HPV-infected women (Hippelainen et al, 1994; Nicolau et al, 2005), only 52% harbored the same HPV subtypes (Reiter et al, 2010). Moreover, penile intra-epithelial neoplasia is rare and detected in less than 2% of the men in contact with oncogenic HPV (Giraldo et al, 2008). We thus analyzed HPV infection and anti-HPV16 E2 blood T-cell responses in asymptomatic male partners chronically exposed to HPV16 during sexual intercourses with their wives affected with usual VIN (Jacobelli et al, 2011, unpublished data). We had hypothesized that male partners exposed to replicative HPV16 could develop immunologic responses against the

early E2 viral protein and thus clear infection. In the absence of condom usage for at least 6 months, the male partners of women presenting with usual VIN could be contaminated by HPV16. HPV16 and HPV27 (a cutaneous HPV) were identified in genital sampling gathered by cytobrush in only two of the eight healthy partners. Such a prevalence of contamination by HPV16 is similar to the one usually observed in male partner of oncogenic HPV-infected women (Reiter et al, 2010). In this male population, we have chosen to study anti-HPV16 E2 T-cell responses because E2 protein is an early highly expressed protein. E2 is bigger than E6 and E7 proteins and induces more T-cell responses than E6 and E7. Therefore looking for an E2-specific response is then more sensitive. In addition, E2 is required for replication and the detection of E2-specific T cell responses is the signature of viral replication. The study of anti-E2 T-cell responses is then more appropriate for the early phases of HPV16 infection as supposed in male partners of women having usual VIN. We have observed HPV16-E2-specific proliferative responses in seven and intracellular cytokine synthesis of single IFN γ , dual IFN γ /IL2 and single IL2 in six out of the seven partners. Since there is no E2 protein in the viral particle, the high frequency of E2-specific T cells responses in partners of women with usual VIN demonstrates that the virus replicate in males.

These E2 specific T-cell responses indicate a striking correlation in all male partners but two between the absence of the HPV-related lesion. The presence of spontaneous E2-specific proliferative T-cell responses and single IFN γ , dual IFN γ /IL2, single IL2 T-cell producers was previously described in other viral systems (Harari et al, 2006; Pantaleo et al, 2006). These polyfunctional anti-E2 T-cell responses could be due to an efficient presentation of viral antigens by dendritic cells present in mucosal tissue and it is tempting to speculate that E2-specific responses are responsible for the clearing of the lesion. Therefore, spontaneously HPV control is related to the presence of memory polyfunctional CD4 $^{+}$ T-cells in male partners.

8. Why the prophylactic vaccine could be useful in men?

The analysis of E2 specific T cell responses is a sensitive and reliable tool to analyze disease progression and the natural history of HPV infection. In six out of eight male partners, the presence of T-cell proliferative responses and single IL2, dual IFN γ /IL2, single IFN γ memory T-cells against HPV16 E2 peptides was concomitant to the control of genital HPV lesions despite HPV16 exposure. These results are reminiscent of those described in Gambian prostitutes exposed to HIV with presence of anti-HIV cytotoxic T lymphocytes without any detectable HIV (Rowland-Jones et al, 1995). Such anti-viral immune T cells responses thus reflect an undetectable viral infection. Our experimental results demonstrate for the first time that, although not clinically detectable, HPV16 can replicate in men and can induce a strong memory T cell response against one of an early viral protein. The presence of polyfunctional (IL2, IFN γ /IL2 and IFN γ secretions and proliferation) anti E2 CD4 $^{+}$ T-cell responses in asymptomatic men unambiguously establishes that E2 is a marker of HPV infection even when undetectable lesions. Responses represent correlates of protective antiviral immunity in HPV infection. Monofunctional (production of IFN γ by IFN γ -ELISpot) “anti-E2 T-cell” responses does not allow HPV16 control. These results suggest that male are an important reservoir of HPV and provide a strong argument in favor of prophylactic HPV vaccination of young men with VLPs to decrease HPV16 infection in men, viral transmission from men to women and thus fight against the spread of mucosal HPV diseases in the population.

9. How to cure usual VIN? Therapeutic vaccines

Preventive vaccines do not address the current need for better treatment for women previously infected by HPV 16 or 18. Other types of vaccines must be used to increase or induce new specific anti-HPV cellular immunity (CD4+ and CD8+ T lymphocytes) in order to kill transformed epithelial cells. Several approaches can be used in this aim. To stimulate cytotoxic or antiviral CD8+ T lymphocytes, the vaccines must target the cytoplasm of dendritic cells. The degradation of vaccine antigens by proteasomes results in short peptides that can bind to HLA class I molecules and migrate at the surface of dendritic cells. To stimulate CD4+ T lymphocytes, endocytosis of vaccinal antigens is essential, followed by degradation of antigens by lysosome/endosome in large peptides that associate with HLA class II molecules before migrating at the surface of dendritic cells. All these therapeutic vaccines must target E6 and E7 viral proteins and contain recombinant viruses (vaccinia viruses for example), DNA or peptides.

Recently, an open clinical trial was performed by the Melief's group (Kenter et al, 2009) in twenty women presenting with usual VIN using 13 large peptides spanning the whole E6 and E7 proteins. Forty five percent of complete (9/20 women) and 25 % (5/20) of partial remission were observed 12 months after immunization. These important results would be even more interesting if the investigators had included a placebo group (Bourgault Villada, 2010a). A new trial with a placebo group is currently under way.

Vaccinia virus was also used in a recombinant vaccine containing E6 and E7 genes from HPV16 and HPV18 (TA-HPV) to vaccinate usual VIN patients. A clinical complete or partial response was observed in 8/18 treated women (Davidson et al, 2003). More recently, vaccination against usual VIN was also performed with another recombinant vaccinia virus, TA-L2E6E7 from HPV16 (Daayana et al, 2010). Two months before vaccination, 19 women were treated by topical imiquimod and then vaccinated by intramuscular route with 3 doses of recombinant vaccinia virus. Imiquimod is an immunomodulator that increases the synthesis of type I IFN by dendritic cells after its fixation to the TLR7 in human dendritic cells. Complete remission was obtained in 58% of vaccinated women.

10. How to determine the epitopic regions for a therapeutic vaccine?

In a study including 16 women presenting with usual VIN, we have determined the strongly immunogenic regions from HPV16 E6 and E7 proteins for CD4+ and/or CD8+ T lymphocytes (Bourgault Villada et al, 2010b). Among 18 large peptides of the proteins E6 and E7, two were recognized in proliferative assays as immunodominant by T cells from 10 out of 16 women (62%) at the entry in the study, namely E6/2 (aa 14-34) and E6/4 (aa 45-68) peptides. Four other peptides, E6/7 (aa 91-110), E7/2 (aa 7-27), E7/3 (aa 21-40) and E7/7 (aa 65-87) were recognized by only 12% of the women in proliferative or IFN γ -ELISpot tests. The regions of E6 and E7 proteins implicated in T cell recognition during HPV infection were not yet well defined because of the usually low frequency of anti-HPV blood T cell responses and of the difficulties of their study.

In protein E6, some peptides included in, including or overlapping our peptides E6/2 (aa 14-34) and E6/4 (aa 45-68) have already been described as preferentially recognized by CD4+ T cells. Among them, peptide E6 42-57 that is restricted by HLA-DR7 has already

been identified (Strang et al, 1990). Regions E6 1-31, 22-51 and 24-45 can be also immunogenic for CD4⁺ T cells as shown in CIN or sexually active healthy women (Kadish et al, 1997). The region E6 42-71, which includes peptide E6/4 (aa 45-68), has also been described as a target of proliferative responses in CIN patients (Kadish et al, 1997). Another E6 111-158 region was previously described as inducing proliferative responses in infected asymptomatic subjects or in patients with CIN3 (Kadish et al, 1997; Strang et al, 1990) as well as E6 127-141 peptide in healthy young women (Gallagher et al, 2007). Similarly, peptides E7 43-77, E7 50-62 and E7 58-68 which are restricted by DR3, DR15 and DR17, respectively, were defined as epitopic peptides for CD4⁺ T cells (Strang et al, 1990; van der Burg et al, 2001; Wang et al, 2009). E7 region 51-98, including our E7/7 (aa 65-87) peptide, is also very immunogenic for proliferating T lymphocytes (de Gruijl et al, 1998; Luxton et al, 1996; Nakagawa et al, 1996).

The characterization of E6 and E7 HPV-16 epitopes and the HLA restriction of their recognition by CD8⁺ T lymphocytes are more precise: E6 29-38, E7 11-20, E7 82-90 and E7 86-93 epitopes are presented by HLA-A2 (Evans et al, 2001; Rensing et al, 1995, 1996), E6 80-88 and E7 44-52 by HLA-B18 (Bourgault Villada et al, 2000) and E6 49-57 by HLA-A24 (Morishima et al, 2007). In women who cleared HPV 16 infection, cytotoxic T lymphocytes (CTL) responses are directed against epitopes preferentially located in the N-terminal half of the E6 protein (region 16-40) (Nakagawa et al, 2005). In this fragment, the dominant epitope E6 29-37 is restricted by HLA-B48, E6 31-38 by HLA-B4002 and the subdominant epitope E6 52-61 by HLA-B35 (Nakagawa et al, 2007). The same group had also shown that the peptide E6 33-42 is recognized by CD8⁺ T lymphocytes in association with HLA-A68, peptide E6 52-61 in association with HLA-B57 and -B35, peptide E6 75-83 in association with HLA-B62, peptide E7 7-15 in association with HLA-B48 and peptide E7 79-87 in association with HLA-B60 (Nakagawa et al, 2004, 2007; Wang et al, 2008). In addition, E7 7-15 is also able to bind HLA-A2 and -B8 to be recognized by CTL (Oerke et al, 2005; Rensing et al, 1995). From the latter results, two hot spots of CD8⁺ T-cell epitopes in protein E6 may be located in the regions E6 29-38 and 52-61 and another one in protein E7 (E7 7-15) (Nakagawa et al, 2007). Nevertheless, a poor immunogenicity of E7 protein was observed in many studies during both HPV 16 infection and after peptidic vaccination using long peptides spanning both E6 and E7 (Kenter et al, 2008; Welters et al, 2008) such as those used in our study.

The epitopes E6/2 (aa 14-34) and E6/4 (aa 45-68) hence could be strongly recognized by CD4⁺ and / or CD8⁺ T lymphocytes and could be particularly relevant in the design of a peptide vaccination. We may hypothesize that the T cell responses that we observed were able to contain the tumor cells into the epithelium. Therefore, E6/2 (aa 14-34) and E6/4 (aa 45-68) peptides could play a major role in the protection against invasive cancer by stimulating T lymphocytes. Specific CD4⁺ T-cells play an essential role in the defense against HPV in particular in women presenting with usual VIN and their male partners.

11. References


- Arends, M. J., Benton, E. C., McLaren, K. M., Stark, L. A., Hunter, J. A., & Bird, C. C. (1997). Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. *Br J Cancer* 75:722-8.

- Berumen, J., Casas, L., Segura, E., Amezcua, J. L., & Garcia-Carranca, A. (1994). Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to the retention of E1/E2 genes. *Int J Cancer* 56:640-5.
- Boulanger, J. C., Sevestre, H., Bauville, E., Ghighi, C., Harlicot, J. P., & Gondry, J. (2004). [Epidemiology of HPV infection]. *Gynecol Obstet Fertil* 32:218-23.
- Bourgault Villada, I., Beneton, N., Bony, C., Connan, F., Monsonego, J., Bianchi, A., Saiag, P., Levy, J. P., Guillet, J. G., & Choppin, J. (2000). Identification in humans of HPV-16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA-B18 and determination of the HLA-B18-specific binding motif. *Eur J Immunol* 30:2281-9.
- Bourgault Villada, I., Moyal Barracco, M., Ziol, M., Chaboissier, A., Barget, N., Berville, S., Paniel, B., Jullian, E., Clerici, T., Maillere, B., & Guillet, J. G. (2004). Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. *Cancer Res* 64:8761-6.
- Bourgault Villada, I. (2010a). Vaccination against HPV-16 for vulvar intraepithelial neoplasia. *N Engl J Med* 362:655-6.
- Bourgault Villada, I., Moyal Barracco, M., Berville, S., Bafounta, M. L., Longvert, C., Premel, V., Villefroy, P., Jullian, E., Clerici, T., Paniel, B., Maillere, B., Choppin, J., & Guillet, J. G. (2010b). Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins. *Clin Exp Immunol* 159:45-56.
- Buckley, J. D., Harris, R. W., Doll, R., Vessey, M. P., & Williams, P. T. (1981). Case-control study of the husbands of women with dysplasia or carcinoma of the cervix uteri. *Lancet* 2:1010-5.
- Coleman, N. H., Birley D, Renton, A. M., Hanna, N. F., Ryait, B. K., Byrne, M., Taylor-Robinson, D., & Stanley, M. A. (1994). Immunological events in regressing genital warts. *Am J Clin Pathol* 102: 768-74.
- Collins, S. I., Constandinou-Williams, C., Wen, K., Young, L. S., Roberts, S., Murray, P. G., & Woodman, C. B. (2009). Disruption of the E2 gene is a common and early event in the natural history of cervical human papillomavirus infection: a longitudinal cohort study. *Cancer Res* 69:3828-32.
- Daayana, S., Elkord, E., Winters, U., Pawlita, M., Roden, R., Stern, P. L., & Kitchener, H. C. (2010). Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. *Br J Cancer* 102:1129-36.
- Davidson, E. J., Boswell, C. M., Sehr, P., Pawlita, M., Tomlinson, A. E., Mcvey, R. J., Dobson, J., Roberts, J. S., Hickling, J., Kitchener, H. C., & Stern, P. L. (2003). Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. *Cancer Res* 63:6032-41.
- De Gruijl, T. D., Bontkes, H. J., Walboomers, J. M., Stukart, M. J., Doekhie, F. S., Remmink, A. J., Helmerhorst, T. J., Verheijen, R. H., Duggan-Keen, M. F., Stern, P. L., Meijer, C. J., & Scheper, R. J. (1998). Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study. *Cancer Res* 58:1700-6.
- De Jong, A., Van Poelgeest, M. I., Van Der Hulst, J. M., Drijfhout, J. W., Fleuren, G. J., Melief, C. J., Kenter, G., Offringa, R., & Van Der Burg, S. H. (2004). Human papillomavirus

- type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. *Cancer Res* 64:5449-55.
- Desaintes, C., & Demeret, C. (1996). Control of papillomavirus DNA replication and transcription. *Semin Cancer Biol* 7:339-47.
- Dillon, S., Sasagawa, T., Crawford, A., Prestidge, J., Inder, M. K., Jerram, J., Mercer, A. A., & Hibma, M. (2007). Resolution of cervical dysplasia is associated with T-cell proliferative responses to human papillomavirus type 16 E2. *J Gen Virol* 88:803-13.
- Evans, M., Borysiewicz, L. K., Evans, A. S., Rowe, M., Jones, M., Gileadi, U., Cerundolo, V., & Man, S. (2001). Antigen processing defects in cervical carcinomas limit the presentation of a CTL epitope from human papillomavirus 16 E6. *J Immunol* 167:5420-8.
- Fausch, S. C., Da Silva, D. M., & Kast, W. M. (2005). Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells. *Vaccine* 23:1720-9.
- Gallagher, K. M., & Man, S. (2007). Identification of HLA-DR1- and HLA-DR15-restricted human papillomavirus type 16 (HPV16) and HPV18 E6 epitopes recognized by CD4+ T cells from healthy young women. *J Gen Virol* 88:1470-8.
- Ghosh, A. K., & Moore M. (1992). Tumour-infiltrating lymphocytes in cervical carcinoma. *Eur J Cancer* 28A: 1910-6.
- Giraldo, P. C., Eleuterio, J., Jr., Cavalcante, D. I., Goncalves, A. K., Romao, J. A., & Eleuterio, R. M. (2008). The role of high-risk HPV-DNA testing in the male sexual partners of women with HPV-induced lesions. *Eur J Obstet Gynecol Reprod Biol* 137:88-91.
- Giuliano, A. R., Lee J. H., Fulp, W., Villa, L. L., Lazcano, E., Papenfuss, M. R., Abrahamsen, M., Salmeron, J., Anic, G. M., Rollison, D. E., & Smith, D. (2011). Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. *Lancet* 377: 932-40.
- Harari, A., Dutoit V., Cellerai, C., Bart, P. A., Du Pasquier, R. A., & Pantaleo, G et al. (2006). Functional signatures of protective antiviral T-cell immunity in human virus infections. *Immunol Rev* 211: 236-54.
- Hippelainen, M. I., Yliskoski, M., Syrjanen, S., Saastamoinen, J., Hippelainen, M., Saarikoski, S., & Syrjanen, K. (1994). Low concordance of genital human papillomavirus (HPV) lesions and viral types in HPV-infected women and their male sexual partners. *Sex Transm Dis* 21:76-82.
- Hopfl, R., Heim K., Christensen, N., Zumbach, K., Wieland, U., Volgger, B., Widschwendter, A., Haimbuchner, S., Muller-Holzner, E., Pawlita, M., Pfister, H., & Fritsch, P. (2000). Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. *Lancet* 356: 1985-6.
- Jacobelli S., Sanaa. F., Moyal Barracco M., Pelisse M., Berville S., Villefroy P., North M.O., Figueiredo S., Charmeteau B., Clerici T., Plantier F., Dupin N., Avril M.F., Guillet J.G., & Bourgault Villada I. (2011). Anti-HPV16 E2 protein T-cell responses and viral control in women with usual vulvar intraepithelial neoplasia and their healthy partners. *Submitted*.
- Kadish, A. S., Ho, G. Y., Burk, R. D., Wang, Y., Romney, S. L., Ledwidge, R., & Angeletti, R. H. (1997). Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia. *J Natl Cancer Inst* 89:1285-93.

- Kenter, G. G., Welters, M. J., Valentijn, A. R., Lowik, M. J., Berends-Van Der Meer, D. M., Vloon, A. P., Drijfhout, J. W., Wafelman, A. R., Oostendorp, J., Fleuren, G. J., Offringa, R., Van Der Burg, S. H., & Melief, C. J. (2008). Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. *Clin Cancer Res* 14:169-77.
- Kenter, G. G., Welters, M. J., Valentijn, A. R., Lowik, M. J., Berends-Van Der Meer, D. M., Vloon, A. P., Essahsah, F., Fathes, L. M., Offringa, R., Drijfhout, J. W., Wafelman, A. R., Oostendorp, J., Fleuren, G. J., Van Der Burg, S. H., & Melief, C. J. (2009). Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *N Engl J Med* 361:1838-47.
- Luxton, J. C., Rowe, A. J., Cridland, J. C., Coletart, T., Wilson, P., & Shepherd, P. S. (1996). Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals. *J Gen Virol* 77 (Pt 7):1585-93.
- Morishima, S., Akatsuka, Y., Nawa, A., Kondo, E., Kiyono, T., Torikai, H., Nakanishi, T., Ito, Y., Tsujimura, K., Iwata, K., Ito, K., Koder, Y., Morishima, Y., Kuzushima, K., & Takahashi, T. (2007). Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope. *Int J Cancer* 120:594-604.
- Nakagawa, M., Stites, D. P., Farhat, S., Judd, A., Moscicki, A. B., Canchola, A. J., Hilton, J. F., & Palefsky, J. M. (1996). T-cell proliferative response to human papillomavirus type 16 peptides: relationship to cervical intraepithelial neoplasia. *Clin Diagn Lab Immunol* 3:205-10.
- Nakagawa, M., Kim, K. H., & Moscicki, A. B. (2004). Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins. *Clin Diagn Lab Immunol* 11:889-96.
- Nakagawa, M., Kim, K. H., & Moscicki, A. B. (2005). Patterns of CD8 T-cell epitopes within the human papillomavirus type 16 (HPV 16) E6 protein among young women whose HPV 16 infection has become undetectable. *Clin Diagn Lab Immunol* 12:1003-5.
- Nakagawa, M., Kim, K. H., Gillam, T. M., & Moscicki, A. B. (2007). HLA class I binding promiscuity of the CD8 T-cell epitopes of human papillomavirus type 16 E6 protein. *J Virol* 81:1412-23.
- Nicolau, S. M., Camargo, C. G., Stavale, J. N., Castelo, A., Dore, G. B., Lorincz, A., & De Lima, G. R. (2005). Human papillomavirus DNA detection in male sexual partners of women with genital human papillomavirus infection. *Urology* 65:251-5.
- Oerke, S., Hohn, H., Zehbe, I., Pilch, H., Schicketanz, K. H., Hitzler, W. E., Neukirch, C., Freitag, K., & Maeurer, M. J. (2005). Naturally processed and HLA-B8-presented HPV16 E7 epitope recognized by T cells from patients with cervical cancer. *Int J Cancer* 114:766-78.
- Ostor, A. G. (1993). Natural history of cervical intraepithelial neoplasia: a critical review. *Int J Gynecol Pathol* 12:186-92.
- Pantaleo, G., & Harari A. (2006). Functional signatures in antiviral T-cell immunity for monitoring virus-associated diseases. *Nat Rev Immunol* 6: 417-23.
- Reiter, P. L., Pendergraft, W. F., 3rd, & Brewer, N. T. (2010). Meta-analysis of human papillomavirus infection concordance. *Cancer Epidemiol Biomarkers Prev* 19:2916-31.

- Reiter, P. L., Pendergraft, W. F., 3rd, & Brewer, N. T. (2010). Meta-analysis of human papillomavirus infection concordance. *Cancer Epidemiol Biomarkers Prev* 19:2916-31.
- Rowland-Jones, S., Sutton J., Ariyoshi, K., Dong, T., Gotch, F., McAdam, S., Whitby, D., Sabally, S., Gallimore, A., & Corrah, T. (1995). HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. *Nat Med* 1: 59-64.
- Srodon, M., Stoler, M. H., Baber, G. B., & Kurman, R. J. (2006). The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). *Am J Surg Pathol* 30:1513-8.
- Strang, G., Hickling, J. K., Mcindoe, G. A., Howland, K., Wilkinson, D., Ikeda, H., & Rothbard, J. B. (1990). Human T cell responses to human papillomavirus type 16 L1 and E6 synthetic peptides: identification of T cell determinants, HLA-DR restriction and virus type specificity. *J Gen Virol* 71 (Pt 2):423-31.
- Sun, X. W., Kuhn, L., Ellerbrock, T. V., Chiasson, M. A., Bush, T. J., & Wright, T. C., Jr. (1997). Human papillomavirus infection in women infected with the human immunodeficiency virus. *N Engl J Med* 337:1343-9.
- Van Der Burg, S. H., Rensing, M. E., Kwappenberg, K. M., De Jong, A., Straathof, K., De Jong, J., Geluk, A., Van Meijgaarden, K. E., Franken, K. L., Ottenhoff, T. H., Fleuren, G. J., Kenter, G., Melief, C. J., & Offringa, R. (2001). Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes. *Int J Cancer* 91:612-8.
- van Seters, M., van Beurden M., & de Craen, A. J (2005). Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. *Gynecol Oncol* 97(2): 645-51.
- Wang, X., Moscicki, A. B., Tsang, L., Brockman, A., & Nakagawa, M. (2008). Memory T cells specific for novel human papillomavirus type 16 (HPV16) E6 epitopes in women whose HPV16 infection has become undetectable. *Clin Vaccine Immunol* 15:937-45.
- Wang, X., Santin, A. D., Bellone, S., Gupta, S., & Nakagawa, M. (2009). A novel CD4 T-cell epitope described from one of the cervical cancer patients vaccinated with HPV 16 or 18 E7-pulsed dendritic cells. *Cancer Immunol Immunother* 58:301-8.
- Welters, M. J., de Jong A., van den Eeden, S. J., van der Hulst, J. M., Kwappenberg, K. M., Hassane, S., Franken, K. L., Drijfhout, J. W., Fleuren, G. J., Kenter, G., Melief, C. J., Offringa, R., & van der Burg, S. H. (2003). Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. *Cancer Res* 63(3): 636-41.
- Welters, M. J., Kenter, G. G., Piersma, S. J., Vloon, A. P., Lowik, M. J., Berends-Van Der Meer, D. M., Drijfhout, J. W., Valentijn, A. R., Wafelman, A. R., Oostendorp, J., Fleuren, G. J., Offringa, R., Melief, C. J., & Van Der Burg, S. H. (2008). Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. *Clin Cancer Res* 14:178-87.
- Xue, Y., Bellanger, S., Zhang, W., Lim, D., Low, J., Lunny, D., & Thierry, F. (2010). HPV16 E2 is an immediate early marker of viral infection, preceding E7 expression in precursor structures of cervical carcinoma. *Cancer Res* 70:5316-25.



Intraepithelial Neoplasia

Edited by Dr. Supriya Srivastava

ISBN 978-953-307-987-5

Hard cover, 454 pages

Publisher InTech

Published online 08, February, 2012

Published in print edition February, 2012

The book "Intraepithelial neoplasia" is till date the most comprehensive book dedicated entirely to preinvasive lesions of the human body. Created and published with an aim of helping clinicians to not only diagnose but also understand the etiopathogenesis of the precursor lesions, the book also attempts to identify its molecular and genetic mechanisms. All of the chapters contain a considerable amount of new information, with an updated bibliographical list as well as the latest WHO classification of intraepithelial lesions that has been included wherever needed. The text has been updated according to the latest technical advances. This book can be described as concise, informative, logical and useful at all levels discussing thoroughly the invaluable role of molecular diagnostics and genetic mechanisms of the intraepithelial lesions. To make the materials easily digestible, the book is illustrated with colorful images.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Isabelle Bourgault-Villada (2012). Current Insight into Specific Cellular Immunity of Women Presenting with HPV16- Related Vulvar Intra-Epithelial Neoplasia and Their Partners, Intraepithelial Neoplasia, Dr. Supriya Srivastava (Ed.), ISBN: 978-953-307-987-5, InTech, Available from:

<http://www.intechopen.com/books/intraepithelial-neoplasia/current-insight-into-specific-cellular-immunity-of-women-presenting-with-hpv16-related-vulvar-intra->

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2012 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen